Moreover, we observed that SLC50A1 enhances the resistance of HCC cells to Doxorubicin (DOX) and 2-deoxy-D-glucose (2-DG), and it facilitates DNA damage repair in DOX-treated HCC cells through the glycolytic pathway. Here, SLC50A1 is linked to hepatocellular carcinoma.